Objective To improve life expectancy and prevent premature mortality in women with Marfan's syndrome. Methods During the development of a regional genetic register for Marfan's Syndrome the outcome of 91 pregnancies in 36 women with this condition was established retrospectively and the cardiovascular and obstetric complications documented. Results No patient had a significant cardiovascular abnormality limiting function before her pregnancy. Of 36 women, four had an aortic dissection relating to pregnancy and two others required aortic surgery following delivery. Thirty women had uncomplicated gestational histories. The incidence of obstetric complications did not exceed expectation. Conclusions Women with Marfan's syndrome are at significant risk of aortic dissection in pregnancy even in the absence of preconceptional cardiovascular abnormality. Aortic root dilatation may be a predictor of risk but dissection may occur without significant dilatation. Guidelines for obstetric care are suggested and preconceptional assessment recommended.
Aim-To examine evolution of the physical characteristics of Marfan's syndrome throughout childhood. Methods-40 children were ascertained during the development of a regional register for Marfan's syndrome. Evolution of the clinical characteristics was determined by repeat evaluation of 10 patients with sporadic Marfan's syndrome and 30 with a family history of the condition. DNA marker studies were used to facilitate diagnosis in those with the familial condition. Results-Musculoskeletal features predominated and evolved throughout childhood. Gene tracking enabled early diagnosis in children with familial Marfan's syndrome. Conclusions-These observations may aid the clinical diagnosis of Marfan's syndrome in childhood, especially in those with the sporadic condition. Gene tracking has a role in the early diagnosis of familial Marfan's syndrome, allowing appropriate follow up and preventive care. (Arch Dis Child 1997;76:41-46)
Objective-To examine the cycle length of the junctional tachycardia often seen during successful slow pathway ablation for atrioventricular (AV) node re-entrant tachycardia, to determine whether shorter cycle lengths predict imminent atrioventricular block. Design-Retrospective analysis of consecutive patients undergoing slow pathway modification. Intracardiac recordings were analysed after digital storage to determine the development of junctional tachycardia, its duration and maximum, minimum, and mean cycle length, occurrence of heart block, persistent slow pathway conduction, or later confirmed recurrence of AV node re-entrant tachycardia. Setting-Regional cardiac centre. Patients-136 consecutive patients undergoing electrophysiological study found to have typical "slow-fast" AV node re-entrant tachycardia and subject to 137 slow pathway modification procedures. Results-During successful temperature feedback controlled radiofrequency energy application, junctional tachycardia developed in 133 of 137 procedures. During ablation, 10 patients had evidence of AV block (first degree in seven patients and third degree in three), and 17 others had retrograde junctional atrial (JA) block. In these 27 patients, the junctional tachycardia was rapid, with a minimum (SD) cycle length 291 (47) ms. Conduction recovered quickly in all but two patients, one of whom required permanent pacing. Junctional tachycardia with normal AV and JA conduction in the other 111 patients was of a significantly slower minimum cycle length (537 (123) ms; p < 0.0001). Conclusions-Fast junctional tachycardia with cycle lengths under 350 ms seen during slow pathway modification is a predictor of conduction block, suggesting proximity to the compact node. Radiofrequency energy application should be terminated immediately to prevent development of AV block. An "auto cut oV" facility for cycle lengths shorter than 350 ms could be built into radiofrequency ablation systems to increase safety. (Heart 2001;85:44-47)
Objective-To evaluate patient acceptability of submuscular implantation of a cardioverter defibrillator (ICD) under local anaesthesia with conscious sedation. Design-Retrospective review. Patient acceptability in the second half of the study was routinely assessed within 24 hours. Setting-Regional cardiac centre. Patients-45 consecutive patients with either aborted sudden death or haemodynamically unstable ventricular tachycardia were referred for ICD implantation. Interventions-A subpectoral implantation technique was employed. Twelve procedures were performed under general anaesthesia. Thirty three patients were sedated with midazolam and diamorphine, and local anaesthesia was achieved with bupivicaine. Ventricular fibrillation for defibrillation threshold testing was induced by alternating current, T wave shock, or ultrarapid burst pacing. Patients were contacted after the procedure to assess acceptability. Results-32 patients having implantation under local anaesthesia did not recall the surgical procedure. One patient described an awareness of "pushing" as the generator was positioned in the pocket. Seven patients said that the procedure was painless but recalled a test shock, four describing it as mildly uncomfortable. All 33 patients stated that they would be willing to have a second implant under local anaesthesia. Twelve patients who had the implant performed under general anaesthesia had no recollection of the procedure. Mean (SD) total procedure duration was significantly longer in those who had general anaesthesia (93 (16) v 67 (17) minutes; p = 0.0009). Conclusions-Subpectoral implantation of ICDs may be performed safely with patient acceptability under local anaesthesia with conscious sedation. (Heart 1998;79:253-255)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.